bluuebunny/crossref_metadata_2025 huggingface dataset:
P777Changes in glycated hemoglobin in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Authors: Stassinos V , Bezati S , Leftheriotis D , Kardamis C , Dourvas P , Katsaras D , Loisiou M , Draganigos A , Klonou E , Flevari P
Published: October 2019

Introduction

Glycemic control reflected by glycated hemoglobin (HbA1c) is regarded as a risk factor and a strong predictor of mortality in patients with heart failure (HF). Hyperglycemia may contribute to oxidative stress, endotelial dysfunction and cardiac fibrosis and influence negatively heart failure prognosis in patients with or without diabetes. Treatment with neprilysin inhibitors in combination with angiotensin II receptor antagonist,(ARNIs) has shown beneficial effects in morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF).

Purpose

We sought to investigate eventual reductions in HbA1c in patients receiving the novel therapy.

Methods

We enrolled a total of 52 stable patients with HFrEF eligible for treatment with ARNIs. Patients were administered a target dose of 200mg bid (97mg sacubitril/103mg valsartan) and we measured HbA1c before, 3months and 6months after initiation of therapy. Changes in HbA1c levels were tested with General Linear Model Repeated Measures test. Spearmans' Rho correlation analysis was performed to investigate possible relationship between the above.

Results

Mean age was 62±10 years, 69,2% of patients were on New York Heart Association (NYHA) functional class II, 23,1% on NYHA III and 7,7% on NYHA IV. 57,7% had ischemic while 42,3% dilated cardiomyopathy, 25% chronic kidney disease and 38,5% diabetes mellitus. Mean Body Mass Index (BMI) was 29,88±4,66 kg/m2. Median value of baseline HbA1c was 5,8% (IQR 0,9). Compared to baseline values, HbA1c decreased to 5,6 (IQR 0,9) and 5,7 (IQR 0,83) (p=0,012) at three and six months of treatment, respectively. Change in HbA1c levels was associated significantly with the presence of diabetes mellitus (p=0,013) and diabetic patients showed greater relative reduction in HbA1c (8%) compared to non diabetic patients (1%). Spearmans' Rho test revealed statistically significant association between changes in HbA1c levels from initiation to three months of therapy, while changes between initiation to six months of administration did non correlate with the presence of diabetes.

Changes in HbA1c

Conclusions

HbA1c levels were reduced significantly during treatment with sacubitril/valsartan. Changes were independent of diabetes in six months of treatment.
P790Verification of selective arterial blood sampling for the assessment of in-hospital mortality in acute decompensated heart failure
Authors: Takahara K , Yasuda K , Oguri M , Ishii H , Murohara T
Published: October 2019

Background

Acidosis or lactate accumulation is frequently observed in patients with acute decompensated heart failure (ADHF). Although each value can be easily obtained and evaluated by arterial blood sampling, sampling to all patients is difficult in daily clinical practice. Therefore, the prognostic impact of acidosis or lactate accumulation on this condition remains to be identified definitively.

Purpose

The purpose of the study was to verify the effectiveness of selective arterial blood sampling at emergency department in patients with ADHF by evaluating an association with in-hospital mortality.

Methods

A total of 917 consecutive patients with ADHF from April 2012 to March 2017 were enrolled. We compared baseline characteristics and in-hospital mortality between patients with or without arterial blood sampling. Patients performed blood sampling were assigned to four groups according to the presence or absence of acidosis (PH <7.35) and lactate accumulation (>2.0 mmol/L), and predictive value of acidosis and/or lactate accumulation for in-hospital mortality was calculated by multivariable logistic regression analysis.

Results

Of all patients, 689 patients (75.1%) underwent blood sampling. Systolic blood pressure and heart rate at hospital arrival, use of emergency medical service, previous heart failure hospitalization, New York Heart Association classification grade IV, presence of jugular vein distention, and the prevalence of hypertension and dementia, were significantly different between the two groups (P<0.05). There was no difference in the occurrence of in-hospital mortality between patients with or without blood sampling (9.3% in patients with blood sampling versus 9.2% in those without blood sampling, respectively; P=0.972). In 689 patients who underwent blood sampling, we examined combined predictive value of acidosis and/or lactate accumulation for in-hospital mortality by multivariable logistic regression analysis with adjustments for covariates with P<0.05 (age, systolic blood pressure at hospital arrival, left ventricular ejection fraction, and cold profile), and showed that acidosis with lactate accumulation [adjusted odds ratio (OR) 3.30, 95% confidence interval (CI) 1.22–8.93, P=0.019], acidosis without lactate accumulation (adjusted OR 4.06, 95% CI 1.12–14.7, P=0.033), lactate accumulation without acidosis (adjusted OR 2.69, 95% CI 1.14–6.33, P=0.024) were significantly (P<0.05) associated with in-hospital mortality. Our results indicated that patients presenting acidosis without lactate accumulation revealed the highest in-hospital mortality among the four groups.

Conclusion

Arterial blood sampling at emergency department could be beneficial for stratifying high risk patients with ADHF. Furthermore, routine blood sampling could be allowed in patients with ADHF if we can secure safety.
P810Novel scoring system for takotsubo syndrome
Authors: Di Vece D , Kato K , Bacchi B , Candreva A , Cammann V L , Szawan K A , Hermes-Laufer J , Micek J , Wischnewsky M , Ghadri J R , Templin C
Published: October 2019

Background

Scoring systems for risk stratification in takotsubo syndrome (TTS) are lacking.

Purpose

The present study aimed to develop a score to predict the overall mortality in TTS.

Methods

TTS patient were enrolled from a multicenter registry. Parameters known to be associated with adverse outcomes in TTS were identified based on current literature. A multivariable analysis including these parameters was conducted and those which were found to be significantly associated with mortality were considered in the scoring system. For each patient, the prognostic score was derived by summing the respective points of each prognostic factor. Based on cut-off values, patients were categorized into four groups including low, intermediate, high, and very high risk.

Results

A total of 1160 patients (90.8% females; mean age 66.5±13.0 years) were included in the present study. Regarding triggering factors, an emotional trigger was identified in 32.6% of TTS patients while 32.1% had preceding physical activities, medical conditions, or procedures and 5.7% had preceding neurologic disorders. The remaining patients (29.7%) had no identifiable triggering factors. According to the results from multivariable analysis, points were assigned to each parameter that was independently associated with long-term mortality: 15 points for neurologic trigger, 10 points for the other physical trigger, 8 points for Age >70 years, 7 points for male sex, 7 points for left ventricular ejection fraction ≤45%, 6 points for diabetes mellitus, 5 points for heart rate >94 bpm on admission, 5 points for systolic blood pressure >140 mmHg on admission, and 2 points for no identifiable trigger. Based on the total points, patients were categorized into four prognostic groups: low-risk ≤15 points (43.5%), intermediate-risk 16–22 points (28.0%), high-risk 23–29 points (18.0%), and very high-risk >29 points (10.5%).

Conclusion

This novel score for risk stratification in TTS only requires easy-obtainable variables to clinicians even in the acute phase and could identify low to very high risk of overall mortality. Thus, it could potentially serve as a useful clinical tool to predict prognosis in patients with TTS.
P813Iatrogenic takotsubo syndrome: incidence and impact
Authors: Ong G J , Stansborough J , Nguyen T H , Horowitz J D
Published: October 2019

Background

Although Takotsubo syndrome (TTS) was once considered to be rare and largely benign, it is now recognised to represent a major cause of cardiac morbidity and mortality, especially in aging women. The biochemical precipitant of attacks of TTS is an increase in catecholamine concentrations within the myocardium, engendering inflammatory activation via biased post-receptor signalling at myocardial β2-adrenoceptor level. Cases of TTS have been reported in patients treated with catecholamines, and with antidepressants which limit catecholamine re-uptake. In the current investigation, we sought to delineate the extent and potential impact of this “iatrogenic” form of TTS.

Methods/Results

Patients' data from a regional registry of 272 consecutive cases of TTS were evaluated. After exclusion of patients (n=14) in whom TTS has occurred in association with life threatening extracardiac disease states, a total of 47 (18%) of patients were identified as having antecedent exposure to potentially “iatrogenic” agents (antidepressants in 29 cases, β2-adrenoceptor agonists in 14). Demographics, including proportion of male patients, did not differ significantly between patients with and without “iatrogenic” TTS, but plasma concentrations of the catecholamine metabolite normetanephrine tended to be greater (median 1160 vs. 950 pmol/L; p=0.07). Long-term survival (median follow-up 3.5 years) was marginally (p=0.09) worse for patients with “iatrogenic” TTS.

Conclusion

(1) A potentially iatrogenic component of precipitation (via iatrogenic elevation of catecholamine levels and β2-adrenoceptor stimulation) is present in a substantial proportion of patients.

(2) In such patients there is an implication of increased long-term mortality risk, potentially accentuated by continued administration of the precipitating agent(s).
P815Tako-Tsubo Cardiomyopathy: clinical correlations of typical and atypical left ventricular contraction patterns
Authors: Gaede L , Herchenbach A , Troebs M , Marwan M , Achenbach S
Published: October 2019

Background

Takotsubo cardiomyopathy (TCM) is diagnosed in 1–2% of all patients presenting with acute coronary syndrome (ACS). Clinical differences in individuals presenting with either the typical (apical) or atypical (midventricular, basal and focal) localization of left ventricular contraction abnormalities are not well understood.

Methods

We retrospectively analyzed 102 consecutive patients diagnosed with TCM based on clinical presentation, coronary angiography, and laevocardiography. Patients with different contraction abnormality patterns were compared regarding sex, clinical presentation, trigger for TCM, LV-function and LV enddiastolic pressure (LVEDP) as well as coronary artery disease.

Results

Of all TCM 102 patients, 69 (68%) presented with the typical pattern of apical contraction abnormality. 33 patients (32%) had an atypical pattern: 22 (22%) with the midventricular type, 2 (2%) with the basal type and 9 (9%) with a focal type. There was no difference in sex distribution among the different types of TCM (female: typical 86% vs atypical 85% p=0.83).

Presentation as a ST-elevation ACS was more common in patients with atypical compared to typical TCM (21% vs. 17%; p=0.85), but without statistical significance. Cardiogenic shock (typical 6% vs atypical 3%; p=0.91) as well as intra-hospital death (typical 3% vs atypical 3%; p=0.56) were rare in both types.

A trigger was not more common in patients with typical TCM (58% vs atypical 55%; p=0.91). The trigger was more often physical in typical (73%) and atypical TCM (78%) than psychological, but the distribution did not differ between the two types (p=0.92).

83.6% of the patients showed an impaired LV-EF. Median LV-EF in patients with typical TCM (35% (IQR 25–40)) tended to be lower than in patients with atypical TCM (40% (IQR 25–40); p=0.63; LV-EF ≤30% typical TCM 45% vs. atypical TCM 39%; p=0.75). In 72% (73/102) of the patients the LVEDP was determined. In 75% (55/73) the LVEDP was elevated (>15mmHg). LVEDP tended to be more often elevated in patients with typical TCM (83% vs. atypical 52%; p=0.11).

Extent of coronary artery disease did not differ in the different types of TCM. Coronary stenosis >50% was rare (typical TCM 20% vs atypical TCM 9%; p=0.26), whereas exclusion of coronary artery disease was common in both types (typical TCM 71%; atypical TCM 76%; p=0.79).

Conclusion

While an apical contraction anomaly is the most common type of presentation in TCM, atypical contraction patterns are found in 32% of the patients. Overall, psychological triggers are not found as frequently in TCM as previously described. Patients with typical and atypical TCM do not differ in clinical presentation, LV-EF, LVEDP and extent of coronary artery disease.
P818Incidence of coronary heart disease in patients with familiar hypercholesterolemia compared to age- and sex- matched controls
Authors: Svendsen K , Walaas Krogh H , Igland J , Holven K B , Mundal L , Tell G S , Leren T P , Retterstol K
Published: October 2019

Background

Familial hypercholesterolemia (FH) is caused by mutations leading to high levels of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary aim was to describe mutations in a large sample of individuals with FH, and compare risk of first-time hospitalization for coronary heart disease (CHD) and acute myocardial infarction (AMI) between FH mutation carriers and healthy controls. The secondary aim was to compare risk of death and re-hospitalization among FH mutation carriers and controls with a first event of CHD and AMI.

Methods

This study is a prospective matched cohort study comprising a sample of 5691 persons with FH and 119 511 age- and sex- matched controls randomly selected from the general Norwegian population. Information on CHD and AMI were obtained from Norwegian Patient Registry, the Cardiovascular Disease in Norway project and the Norwegian Cause of Death Registry. Endpoints are defined according to the International Classification of Diseases, version 9 (ICD9) or version 10 (ICD10). Risk among persons with FH will be compared to healthy controls in terms of hazard ratios (HR) from Cox regression with follow-up time calculated from time of FH-diagnosis for the person with FH in each matched set.

Results

In total 51.8% (n=61866) of the combined sample were women with mean age 49.0±20.3 years, whereas 48.2% (n=57645) were men with mean age 46.8±19.6 years. There were 236 different FH mutations registered among the FH mutation carriers. The most frequent mutation was 313+1g>A, that accounted for 20.7% (n=1178) of the total, followed by C210G with 12.1% (n=690). Results for incidence of CHD, AMI, and mortality after CHD and AMI and readmission rates are not yet available but will be presented at the conference.

Acknowledgement/Funding

The study is funded by South-Eastern Norway Regional Health Authority
P824The clinical impact of polyunsaturated fatty acid on clinical outcomes in acute coronary syndrome with dyslipidemia: HIJ-PROPER sub-analysis
Authors: Nakawaza M , Arashi H , Nomura H , Kawada-Watanabe E , Ogiso M , Sekiguchi H , Yamaguchi J , Ogawa H , Hagiwara N
Published: October 2019

Background

Polyunsaturated fatty acids, especially omega-3 and -6 series, are key essential nutrients that play an important role in humans to maintain cell membranes and function. A recent randomized trial reported that adding eicosapentaenoic acid (EPA) to statins was beneficial to cardiovascular disease patients who had a residual risk factor. Further, several studies have reported that the low baseline value for EPA to arachidonic acid (AA) ratio is related to worse clinical outcome and plaque vulnerability in coronary artery disease patients. However, effects of baseline EPA/AA ratio on clinical outcomes in ACS patients have not been thoroughly evaluated.

Objectives

This study aimed to examine the impact of baseline eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio on clinical outcomes of acute coronary syndrome (ACS) patients and how lipid-lowering therapy affects serum EPA/AA levels in these patients.

Methods

This is a sub-analysis of HIJ-PROPER assessing the effect of aggressive low-density lipoprotein cholesterol (LDL-C)-lowering treatment with pitavastatin+ezetimibe in 1,734 ACS patients with dyslipidemia. Patients were divided into two groups based on EPA/AA level on admission (cut-off: 0.34 μg/mL; median of baseline EPA/AA level) and clinical outcomes were examined.

Results

Percent reduction of LDL-C from baseline to follow-up and mean LDL-C level during follow-up were similar regardless of baseline EPA/AA ratio. In the low EPA/AA group, the Kaplan–Meier estimate for the primary endpoint at 3 years was 27.2% in the pitavastatin+ezetimibe group, compared with 36.6% in the pitavastatin-monotherapy group [hazard ratio (HR), 0.69; 95% confidence interval (CI), 0.52–0.93; P=0.015). However, in the high EPA/AA group, there was no significant reduction in the primary endpoint by pitavastatin+ezetimibe therapy (HR, 0.92; 95% CI, 0.70–1.20; P=0.52).

Conclusions

Aggressive lipid-lowering therapy with ezetimibe had a positive effect on clinical outcomes in the low EPA/AA group of ACS patients with dyslipidemia, but not in the high EPA/AA group. This effect was independent of LDL-C reduction and suggests that EPA/AA measurement on admission in ACS patients contributes to a “personalized” lipid-lowering approach.
P828Low-density lipoprotein cholesterol lowering therapy and target level attainment after a recent myocardial infarction - nationwide cohort study
Authors: Allahyari A , Jernberg T , Lautsch D , Lundman P , Hagstrom E , Schubert J , Boggs R , Salomonsson S , Ueda P
Published: October 2019

Background

Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease after a myocardial infarction (MI). The European Society of Cardiology (ESC) guidelines recommend lipid lowering therapy to reach LDL-C treatment targets after an MI.

Purpose

To assess LDL-C target level attainment according to the ESC guidelines among patients with a recent MI in Sweden.

Methods

We used data from nationwide registers in Sweden and included patients aged 18–74 years admitted to a hospital with MI (1 January 2013–1 October 2016). Among patients who were alive and had LDL-C data available, we assessed LDL-C target achievement at 6–10 weeks (n=21,505) and 12–14 months (n=17,957) after the MI by category of lipid lowering therapy (no statin; low/moderate-intensity statins; high-intensity statins; any statin plus ezetimibe). The target was defined as an LDL-C of <1.8 mmol/L and a ≥50% reduction from the baseline if LDL-C was 1.8–3.5 mmol/L and the patient was not already receiving statins.

Results

Most patients were treated with high-intensity statin monotherapy (84.2% and 72.0%) or any statin with ezetimibe (2.1% and 10.4%) at 6–10 weeks and 12–14 months after the MI, respectively. In total, 37.7% (6–10 weeks) and 38.3% (12–14 months) had attained their LDL-C target. The proportion of patients attaining their LDL-C target at 6–10 weeks was 12% (no statin), 30% (low/moderate-intensity statins), 39% (high-intensity statins), and 49% (any statin plus ezetimibe). The corresponding numbers at 12–14 months were 16% (no statin), 29% (low/moderate-intensity statins), 39% (high-intensity statins), and 58% (any statin plus ezetimibe). A total of 11.8% at 6–10 weeks and 12.3% at 12–14 months reached an LDL-C level of <1.8 mmol/L, but did not reach their LDL-C target level due to the ≥50% reduction criteria. (Figure 1)

Figure 1

Conclusions

In this large population-based study using nationwide data, more than half of patients with a recent MI did not achieve the ESC guidelines LDL-C target levels, despite a large proportion with high-intensity statin therapy. In patients treated with statins and ezetimibe, four out of ten did not reach the ESC LDL-C target level. Our findings indicate that there may be a need for additional LDL-C lowering therapy if the target level is to be attained in all patients.

Acknowledgement/Funding

This project was supported by funding from Merck Sharp & Dohme.
P832LDL-C levels on statins and cardiovascular event risk in stable coronary artery disease: An observation from the REAL-CAD study
Authors: Toyota T , Morimoto T , Iimuro S , Iwata H , Miyauchi K , Inoue T , Nakagawa Y , Daida H , Ozaki Y , Sakuma I , Furukawa Y , Ohashi Y , Matsuzaki M , Nagai R , Kimura T
Published: October 2019

Background

The relation between very low on-treatment low-density lipoprotein cholesterol (LDL-C) level and the cardiovascular event risk is still unclear in patients receiving the same doses of statins.

Methods

From the REAL-CAD study comparing high-dose with low-dose pitavastatin therapy in Japanese patients with stable coronary artery disease, 11105 patients without reported non-adherence for the study drug were divided into 3 groups according to the on-treatment LDL-C level at 6-month (<70 mg/dL, 70–100 mg/dL, and ≥100 mg/dL; N=1016, N=3078, and N=1665 in the pitavastatin 1 mg/day stratum; N=2431, N=2524, and N=391 in the pitavastatin 4 mg/day stratum). Primary outcome measure was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina requiring emergent admission.

Results

In the pitavastatin 1 mg/day stratum, cumulative 4-year incidence of the primary outcome measure was not significantly different across the 3 groups (5.0%, 5.7%, and 5.2%, P=0.51), while in the 4 mg/day stratum, it was significantly higher in the LDL-C ≥100 mg/dL group than in other groups (4.5%, 3.4%, and 9.1%, P<0.001). The adjusted risks of the LDL-C <70 mg/dL group relative to the LDL-C 70–100 mg/dL group (reference) remained insignificant for the primary outcome measure in both 1 mg/day and 4 mg/day strata (HR 0.84, 95% CI 0.58–1.18, P=0.32, and HR 1.25, 95% CI 0.88–1.79, P=0.22). The adjusted risk of LDL-C ≥100 mg/dL group relative to the reference group was not significant for the primary outcome measure in the 1 mg/day stratum (HR 0.82, 95% CI 0.60–1.11, P=0.21), while it was highly significant in the 4 mg/day stratum (HR 3.32, 95% CI 2.08–5.17, P<0.001). In the on-treatment LDL-C ≥100 mg/dL group in the 4 mg/day stratum, LDL-C increased by 6.3 mg/dL from baseline to 6-month despite dose escalation of pitavastatin from 1 mg/day to 4 mg/day, suggesting the presence of unreported poor adherence in this small subgroup.

Adjusted Effects of On-treatment LDL-C

Conclusions

Very low on-treatment LDL-C level (<70 mg/dL) was not associated with lower cardiovascular event risk compared with moderately low on-treatment LDL-C level (70–100 mg/dL) in patients receiving the same doses of statins. Too much emphasis on the target LDL-C strategy might mislead the clinical practice.

Acknowledgement/Funding

The Comprehensive Support Project for Clinical Research of Lifestyle-Related Disease of the Public Health Research Foundation.
P833Two-year clinical outcomes between statin with ACE inhibitor or ARB in patients with ST-segment elevation myocardial infarction after successful PCI with DES
Authors: Kim Y H , Her A.-Y , Jeong M.-H , Kim B.-K , Lee S.-Y , Hong S.-J , Shin D.-H , Ahn C.-M , Kim J.-S , Ko Y.-G , Choi D , Hong M.-K , Jang Y
Published: October 2019

Background

Limited comparative data are available.

Purpose

We decided to compare 2-year major clinical outcomes between statin with ACEI and statin ARB therapy in patients with STEMI after PCI with drug-eluting stents (DES).

Methods

A total 11706 STEMI patients who underwent PCI with DES and who prescribed statin were enrolled and they were divided into two groups, the statin with ACEI group (n=8705) and the statin with ARB group (n=3001). The primary endpoint was the major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-TVR. The secondary endpoints were the cumulative incidences of individual components of MACE and target vessel failure (TVF), a composite of death related to the target vessel, re-MI, or clinically driven TVR.

Results

Two PSM groups (2835 pairs, n=5670, C-statistic = 0.680) were generated. The relative risk of MACE was higher in the statin with ARB group compared to statin with ACEI groups after propensity score-matched (PSM) analysis (hazard ratio [HR]: 1.323, 95% confidence interval [CI]: 1.085–1.613, p=0.006). The relative risks of cardiac death (HR: 1.831, 95% CI: 1.199–2.740, p=0.005), total repeat revascularization (HR: 1.487, 95% CI: 1.133–1.950, p=0.004), and non-TVR (HR: 1.696, 95% CI: 1.122–2.564, p=0.012) were also higher in the statin with ARB group after PSM.

Outcomes Cumulative Events at 2-year (%) Hazard Ratio (95% CI) p value Statin + ACEI Statin + ARB Log-rank Propensity score matched Patients MACE 173 (6.5) 225 (8.5) 0.006 1.323 (1.085–1.613) 0.006 All-cause death 58 (2.2) 80 (3.0) 0.054 1.391 (0.992–1.950) 0.056 Cardiac death 35 (1.3) 63 (2.3) 0.004 1.831 (1.199–2.740) 0.005 Re-MI 39 (1.5) 44 (1.7) 0.548 1.141 (0.742–1.756) 0.548 Total repeat revascularization 88 (3.4) 128 (4.9) 0.004 1.487 (1.133–1.950) 0.004 TLR 26 (1.0) 40 (1.5) 0.075 1.561 (0.953–2.558) 0.077 TVR 53 (2.0) 71 (2.8) 0.086 1.364 (0.955–1.946) 0.088 Non-TVR 36 (1.4) 60 (2.3) 0.011 1.696 (1.122–2.564) 0.012 TVF 140 (5.3) 173 (6.6) 0.050 1.249 (1.000–1.561) 0.050

Conclusions

In this study, we suggest that the combination of statin with ACEI may be beneficial for reducing the cumulative incidences of MACE, total repeat revascularization rate, and non-TVR rather than the statin with ARB after PCI with DES in STEMI patients.
P840Predicting outcome in patients with symptomatic coronary artery disease: A comparison of available risk assessment scores
Authors: Zdanyte M , Wrazidlo R W , Groga-Bada P , Kaltenbach S , Gawaz M , Geisler T , Rath D
Published: October 2019

Introduction

Thromboischemic and bleeding events are rare but potentially life-threatening complications after percutaneous coronary intervention (PCI). Consequently, duration of dual antiplatelet therapy (DAPT) after coronary stent implantation might be altered due to bleeding or thromboischemic risk. Various risk assessment models have been established to predict adverse events in patients with symptomatic coronary artery disease (CAD). The aim of the present study was to compare available scoring systems based on their performance identifying high-risk patients with symptomatic CAD.

Methods and results

1469 patients were included (n=730 stable CAD and n=739 acute coronary syndrome (ACS)). GRACE 2.0, CALIBER, PREDICT-STABLE, PARIS MB, PARIS CTE and DAPT scores were calculated in appropriate patient subgroups. All patients were followed-up for 360 days for all-cause death (ACD), myocardial infarction (MI), ischemic stroke (IS) and bleeding. The primary combined endpoint (CE) consisted of ACD, MI and/or IS. Secondary endpoints were defined as single occurrence of either ACD, MI, IS, or bleeding. Strong discrimination performance for ACD (AUC=0.82) and IS (AUC=0.84) could be shown for PARIS-MB and CALIBER score, respectively. For ACD, good discrimination performance was found for GRACE (AUC=0.79), CALIBER (AUC=0.71), PARIS-CTE (AUC=0.71) and PREDICT-STABLE (AUC=0.70) score, respectively. For CE and bleeding, we could demonstrate good discrimination performance for GRACE (AUC=0.71) and CALIBER (AUC=0.76) score.

Figure 1

Conclusions

In short-term follow-up, several risk assessment models show strong to good discrimination performance for major adverse cardiovascular events. These prediction models might be used to adjust duration of DAPT in patients with symptomatic CAD.

Acknowledgement/Funding

DFG, KFO-274, SFB-TRR 240
P848Prevalence and Prognosis of Familial Hypercholesterolemia (FH) with Acute Myocardial Infarction (AMI) in China: Chinese Acute Myocardial Infarction (CAMI) Registry
Authors: Wu N Q , Yang J G , Li J J , Dong Q T , Guo Y L , Gao Y , Wang Y , Li W , Yang Y J
Published: October 2019

Background

The prevalence and prognosis of familial hypercholesterolemia (FH) with acute myocardial infarction (AMI) in China is unclear.

Purpose

To invistigate the prevalence and prognosis of familial hypercholesterolemia (FH) with acute myocardial infarction (AMI) in China.

Methods

In China Acute Myocardial Infarction (CAMI) Registry, 13,002 patients with age 18–80 were consecutively enrolled with first-onset acute myocardial infarction who were naïve to statin before admission from Januanry 1st, 2013 to October 31st, 2014. According to Dutch Lipid Clinical Network Criteria (DLCNC), the patients were divided to heterozygous familial hypercholesterolemia (HeFH) (definite or probable HeFH, possible HeFH) or no HeFH group. All the patients were followed up (average follow-up period, 24 months) and composite major adverse cardiovascular events (ENDPOINT) were recorded which were defined as all-cause death, non-fatal myocardial reinfarction and stroke. Cox regression was performed to analyze the difference of composite endpoint occurrence between HeFH group and no HeFH group.

Results

The number of the patients in the three groups was as following, 62 in definite or probable HeFH group, 484 in possible HeFH group, 12456 in no HeFH group. The prevalence of HeFH is 4.2% (including 0.47% of definite or probable HeFH, 3.73% of possible FH). The average age of onset of first-time AMI was 54±12,56±12,63±12 years old (p<0.0001) in definite or probable HeFH group, possible HeFH group and no HeFH group, respectively. The percentage of Killip III or above (8.1% vs 4.3% vs 6.3%, p=0.1629), cardiac arrest (1.6% vs 0.6% vs 0.9%, p=0.6990), and TIMI 0–2 grade after primary percutaneous cardiac intervention (PCI) (0% vs 6.8% vs 4.3%, p=0.5866) was not significantly different in definite or probable HeFH group, possible HeFH group and no HeFH group, respectively. After Cox proportional analysis adjusting multiple factors, the rate of composite endpoint during follow-up period was not significantly different (definite or probable HeFH group vs no HeFH group, HR 0. 853, 95% CI 0.381–1.910, p=0.699, possible HeFH group vs no HeFH group, HR1.076, 95% CI 0.795–1.458, p=0.635).

The prognosis of FH with AMI in China

Conclusions

In CAMI Registry, the prevalence of HeFH was 4.2%, the diagnosis of HeFH was not a dependent risk factor for the rate of composite cardiovascular events.
P866Early vascular ageing and acute coronary syndromes in young patients
Authors: Gheorghe-Fronea O F , Ilina A R , Dorobantu M
Published: October 2019

Purpose

To evaluate the prevalence of atherosclerotic coronary lesions in young patients from a very high CV risk country, presented with a first ACS episode and to analyse the association between arterial stiffness, arterial age and the severity of CAD.

Methods

Sixty consecutive patients with age ≤45 years (mean age 41,25±3.99 years; range 22–45 years; 81.7% males) admitted in our department for a first ACS between January 2016 and January 2018 and underwent coronary angiography for evaluation of CAD were enrolled in the study after signing a written informed consent (ACS group) and compared with 60 healthy subjects, age and sex-matched, randomly selected from the SEPHAR III national representative survey's data base. Arterial stiffness parameters and arterial age were measured with an oscillometric device (Arteriograph). Association between arterial age and arterial stiffness and the severity of CAD was assessed by bivariate correlation analysis with adjustments for major confounders.

Results

The main pathogenic mechanism of ACS was represented by the coronarian atherosclerotic lesions (46 cases, representing 76,7%, p<0,001) and the most frequent clinical form was the ST-segment elevation myocardial infarction (53 cases, representing 88,3%, p<0,001). Of all those 46 patients from the SCA that have atherosclerotic lesions, most had univascular disease (univascular – 25 cases, 54.3% vs. bivascular: 14 cases, 30,4% vs. trivascular: 7 cases, 15.2%, p=0.005). ACS group had significantly higher PWVao values than CONTROL group, on average of 2, 87m/s [9,49±1,92 m/s vs. 6,62±1,12/s, p<0.0001; 95% CI = (−3,43m/s; −2,29m/s)]. Arterial age of ACS patients was significantly higher than their own biological age, on average with 5.78 years [mean arterial age 47.03 vs. biological age: 41.25; p<0.0001; 95% CI = (3.91ani; 7.66ani)] while arterial age and biological age were similar in CONTROL group [mean arterial age 40,53 ani vs. mean biological age: 39,63 ani; p=0,207; 95% CI = (−0,73ani; 3,29ani)]. In ACS group, while among patients with normal coronaries, the arterial and biological age were statistically similar (43.25 years vs. 41.53 years; p=0.500), in patients with atherosclerotic lesions (uni-, bi or tri vascular), arterial age was significantly higher compared to biological age, on average with 5.7 years, 5.7 years and 7.5 years respectively. Also, in STEMI group, the severity of CAD was correlated with both PWVao values [rs=0,521 rs2=0.271; p<0,0001] and arterial age [rs=0,512 rs2=0.262; p=0.035].

Conclusions

The results of our study shows that young ACS patients experience an early vascular ageing process reflected by an increased arterial stiffness and significantly higher vascular age compared with normal healthy age and sex-matched controls, leading to an early onset of CAD.

Acknowledgement/Funding

This work was supported by CREDO Project - ID: 49182, financed through the SOP IEC -A2-0.2.2.1-2013-1 cofinanced by the ERDF.
P871Coronary artery aneurysms: clinical features, management and long-term outcomes, insights from the international coronary artery aneurysm registry (CAAR)
Authors: Nunez-Gil I , Cerrato E , Bollati M , Nombela-Franco L , Alfonso E , Camacho Freire S , Villablanca P , Amat Santos I , De La Torre Hernandez J M , Pascual I , Liebetrau C , Camacho B , Pavani M , Feltes G , Fernandez Ortiz A
Published: October 2019

Background

Coronary Aneurysms are a focal dilatation of an artery segment of >1.5-fold the normal size of adjacent segments. Some limited series suggested an incidence of 0.3–12%. However, coronary aneurysms are not mentioned in practice guidelines and several questions remain unanswered.

Purpose

To investigate its clinical profile, prognostic predictors, and long term outcomes.

Methods

The coronary artery aneurysm registry (CAAR, NCT02563626) is a collaborative effort involving 32 hospitals across 9 countries (Canada, Cuba, Czech Republic, Germany, Italy, Netherlands, Spain, USA and Uruguay). When eligibility was uncertain, cases were reviewed by a core lab.

Results

We reviewed 436,467 consecutive angiographies between 2004–2016. 1,565 patients were ambispectively included. Global incidence was 0.35%. Most were male (78.5%) with a mean age of 65 years. Cardiovascular risk factors were frequent. An aortopathy history was present in 8.7% but a Kawasaki antecedent was unfrequent (0.3%).

The main indication for cath was an ACS in 966 cases. Most aneurysms were saccular and 82 giant. The number of aneurisms was low, mainly with 1–2 (95.8%) and only 3 patients with ≥6, proportionally with more coronary stenosis. The most affected artery was the LAD. Aortopathy was related with higher number of aneurysms. Most received any revascularization, commonly percutaneous (PCI). During a follow-up of 37.2 months, 485 suffered a MACE, (death/heart failure/unstable angina/reinfarction) and 240 died. Age, race, diabetes, renal failure, peripheral disease, acute cath, coronary stenosis, LVEF and anticoagulation remained as predictors of death/MACE after multivariate adjustments, without no major differences comparing CABG vs PCI. No restenosis was found in aneurysm with DES but those with BMS suffered 4 (p=0.002). MACE and death were more frequent in patients who received BMS.

Figure 1

Conclusions

Coronary aneurysmal disease is not uncommon. It is associated with severe coronary stenosis and a high cardiovascular risk burden, pointing out an aggressive atherosclerotic status. Antiplatelet therapy is a reasonable option and interventional procedures safe and effective, compared with surgery. Drug eluting stents should be preferred as the default strategy.

Acknowledgement/Funding

None
P891Psycho-social impact of predictive genetic testing in hereditary heart diseases (PREDICT Study)
Authors: Bordet C , Brice S , Maupain C , Gandjbakhch E , Bertrand I , Palmyre A , Moerman A , Toutain A , Odent S , Brehin A C , Staraci S , Richard P , Tezenas Du Montcel S , Gargiulo M , Charron P
Published: October 2019

Introduction

Hereditary heart diseases are most often characterized by autosomal dominant inheritance and delayed cardiac expression. Predictive genetic testing is offered to asymptomatic relatives to allow targeted medical care with early therapeutics in order to reduce the risk of complications. Psychological issues and socio-professional impact of predictive testing are complex and have been poorly studied. The aim of this study was to evaluate the psychological and socio-professional impact of predictive genetic testing in hereditary heart diseases through a prospective and retrospective study.

Patients and methods

This multicentric French study involved 20 expert centers in hereditary heart diseases. We included 517 adult relatives (42.3±16.7 years, 60.6% females) who performed predictive genetic testing (prospective study: N=264, retrospective study: N=253). The opinion and experience were collected via auto-questionnaires, at various moments in the prospective study, with different items and validated scales (STAI: score for anxiety and IES: impact of event).

Results

In the prospective study, family history was characterized by cardiomyopathy (88.4%) and channelopathies (11.6%). The main motivations for performing the test were: “to remove doubt” (65.3%), “for children” (64.0%), “to benefit from medical supervision” (34.9%). A mutation was present in 39.4% of relatives. No regret was expressed after testing (only 2.3% regrets). The result did not lead to a socio-professional change or family relationship change in 60.7%. Among those who had a change, it was perceived as unfavorable for only 3%. A change in socio-professional status and/or family relationship was mainly related to the result of genetic testing (p<0.0001). The level of anxiety (STAI scale) increased before the test result but then decreased and returned to baseline. Subjects with depression history were more likely to develop anxiety at long term after multivariate analyses (p=0.004). Quite similar results were observed in the retrospective study.

Conclusions

Our results show that contrary to a widespread opinion, the medical benefit was not the main motivation for predictive genetic testing. In most cases, no or marginal adverse psychological and socio-professional impact of genetic testing was observed when performed by a team expert in predictive testing. However careful management is required to identify and manage subjects at risk for increased anxiety or socio-professional change.
P896Effects of tafamidis in patients with transthyretin amyloid cardiomyopathy
Authors: Rettl R , Duca F , Binder C , Capelle C , Aschauer S , Badr Eslam R , Mascherbauer J , Hengstenberg C , Bonderman D
Published: October 2019

Background

Transthyretin amyloid cardiomyopathy (ATTR-CA) is caused by deposition of amyloid fibrils in the myocardium. The deposition occurs when transthyretin (TTR) becomes unstable and misfolds. Tafamidis is a kinetic stabilizer of TTR that prevents tetramer dissociation and amyloidogenesis by TTR.

Methods

Eighteen patients with diagnosis of ATTR-CA (hATTR or wtATTR) from our national amyloidosis registry were treated with 20 mg of tafamidis for a period of six months. In our explorative analysis we aimed to evaluate the effects of tafamdis by changes from baseline of the serum NT-proBNP concentration, 6-minute walking distance, as well as cardiac structure and function.

Results

The exploratory analysis showed a decrease in serum NT-proBNP concentration in tafamidis treated patients, compared to increase in untreated patients (median difference, −481.0 pg/mL). Tafamidis improved the walking distance during the 6-minute walk test at month six, compared to baseline (mean, 31.25 m). Echocardiographic findings revealed an improvement of the global longitudinal strain (mean, 0.77%), a decrease in left atrial size (mean, −1.65 mm) and a decrease in left ventricular size (mean, −4.13 mm) in tafamidis treated patients compared to untreated patients. Due to insufficient power the results did not differ significantly between tafamidis treated patients and untreated patients.

Change from baseline Tafamidis No treatment Treatment Difference p-value Cardiac Biomarkers n=18 n=15   NT-proBNP, ng/L Baseline, median 2740.0 2835.0 CFB to 6 months, median −207.0 274.0 −481.0 0.329 Functional Status n=8 n=7   6MWT, m Baseline, mean 441.00 420.50 CFB to 6 months, mean 31.25 −16.50 +47.75 0.373 Echocardiogram n=17 n=15   LA, mm Baseline, mean 63.41 61.33 CFB to 6 months, mean −1.65 0.60 −2.25   LV, mm Baseline, mean 44.13 41.80 CFB to 6 months, mean −4.13 0.33 −4.46 0.075   LV wall thickness, mm Baseline, mean 22.06 18.47 CFB to 6 months, mean 0.68 −0.60 +1.28 0.055   Longitudinal strain, % Baseline, mean −10.66 −12.42 CFB to 6 months, mean 0.77 −1.03 +1.80 0.652 MRI n=7 n=6   ECV, % Baseline, mean 52.26 44.22 CFB to 6 months, mean 0.81 3.70 − 2.89 0.493   LV mass, g Baseline, mean 187.71 170.33 CFB to 6 months, mean 24.29 19,67 +4.62 0.612

Conclusion

Treatment with tafamidis for a period of six months in patients with ATTR-CA leads to positive effects on NT-proBNP level, 6-minute walking distance, as well as cardiac structure and function compared to untreated patients.
P911High rate of cardiac amyloidosis in elderly patients with aortic stenosis: clinical presentation before and after aortic valve intervention
Authors: Zikry Deitch M , Haberman D , Lifshitz S , Tshori S , Fabricant Y , Voldarsky I , Meladin V , Gandelman G , Goland S , George J , Shimoni S
Published: October 2019

Background

Aortic Stenosis (AS) is the most common valvular heart disease in the Western world. Wild-type transthyretin amyloid (wtATTR) affects the heart, causing restrictive cardiomyopathy. Deposits can be found in up to 25% of individuals >85 years of age at autopsy. Recently several reports showed a relatively high prevalence of transthyretin cardiac amyloidosis (TTR-CA) in patients with AS.

Objectives

The aim of this study was to examine the clinical effects of TTR-CA in patients who have undergone aortic valve replacement therapy and evaluate the outcome of the intervention.

Methods

We recruited patients who underwent surgical (AVR) or percutaneous (TAVI) aortic valve intervention between 2011 and 2018. The patients underwent a Tc99m-PYP scan using SPECT technology which has been shown to be valid for the diagnosis of TTR-CA. We reviewed patient files before (time point 1) and after intervention (time point 2) and at 2 years (time point 3) follow up, and collected data on hospitalizations, laboratory, and echocardiography.

Results

The study included 86 patients, mean age 78±6 years, 55% women. Twenty-nine (33%) participants were diagnosed as positive (VAS 2 and 3) for transthyretin cardiac amyloidosis.There were no differences in baseline characteristics between patients with and without TTR-CA in cardiovascular risk factors and co-morbidities, laboratory parameters and nutritional status. There were no differences in baseline echocardiographic parameters including valve gradients and left ventricular hypertrophy. However, the patients with TTR CA had more advanced diastolic dysfunction compared to patients without TTR CA (P=0.03) and higher pulmonary artery pressure (44±14.75mmhg vs 30.5±11.38mmhg, p=0.06). Before the intervention, patients with transthyretin cardiac amyloidosis had 3.26 times more hospitalizations due to heart failure as compared to patients in the negative group (p=0.01).

After the intervention, diastolic function remained more severely affected in the positive group at all follow-up points compared to the negative group (p=0.05). Similar observations were seen in the measurements of pulmonary arterial pressure (p=0.019 at time 2 and p=0.015 at time 3). Consistent with the echocardiographic findings, patients with transthyretin cardiac amyloidosis had 2.84 times more hospitalizations after intervention for heart failure than patients in the negative group (p=0.02).

Conclusions

Co-existence of transthyretin cardiac amyloidosis and aortic stenosis in the older population is associated with a more severe clinical presentation and with more advanced clinical and echocardiographic signs of heart failure. Improvement after valvular intervention might be limited in terms of symptoms and hospitalizations in this subgroup.

Acknowledgement/Funding

None
P914Balloon aortic valve valvuloplasty as palliative therapy in severe aortic valve stenosis: 10 years experience in a single centre
Authors: Mantovani F , Clavel M A , Jayme F , Valli L , De Mola R M , Leuzzi C , Navazio A , Guiducci V
Published: October 2019

Background

Improved technology together with greater operator experience has led to refinement of balloon aortic valve valvuloplasty (BAV) in recent years. It may provide a palliative treatment option in high-risk patients, highly symptomatic, for whom no other invasive therapy is available. However, there has not been universal adoption of BAV as a standalone therapy.

Methods

A retrospective analysis of ten years of practice of BAV as palliative strategy in patient with symptomatic aortic stenosis between March 2008 and June 2018 was performed. Demographic, clinical, procedural, and follow-up data on all patients were collected.

Results

A total of 152 patients (95 women, 63%) with a mean age of 85±6 years underwent BAV. All patients had severe aortic stenosis, were considered not suitable to aortic valve replacement nor Trans-catheter aortic valve implantation (TAVI) for appreciable comorbidity (STS score 9±5) and had severe symptoms mainly of heart failure which required medical attention. A statistically significant decrease in trans-valvular gradient was observed (peak to peak gradient before BAV 52±22 mmHg, after BAV 29±16 mmHg, delta gradient 24±14 mmHg; p<0.0001). Only one patient, who undergone BAV because of cardiogenic shock, died during the procedure. Considering the high-risk population, intra-hospital mortality was low (7 patients died, 4%). Mortality at 1-year follow-up was 43% and survival free from new hospitalization for heart failure was 63% at 1-year follow-up and 53% at 2 years follow-up. 19 patients (13%) required repeated BAV during follow-up.

Conclusion

BAV as a palliative procedure in high-risk patients who are highly symptomatic, has a low operative mortality in our experience. BAV is associated with a significant reduction in aortic valve gradient and is valuable since half of the patients were alive without re-hospitalizations for heart failure at 2 years follow-up.

Acknowledgement/Funding

None